New capabilities provide increased biologically relevant data for improved efficiency in the drug discovery process
The latest version of Operetta's software, Harmony 3.5, enables scientists to track individual cells over time for a better understanding of dynamic processes and to generate more accurate prediction models. (Photo: Business Wire)
Scientists conducting research in the areas of cancer, stem cells or infectious diseases will benefit from the Operetta system's new capabilities to analyze the dynamic behavior of cells using advanced live cell, high content imaging. With the new capabilities, users will be able to accurately observe individual cell behavior over time to better understand dynamic processes in order to generate more accurate prediction models, for example how cancer cells migrate during metastasis or how viruses invade cells.
"We are seeing a trend towards researchers using biological assays that
are better models of the physiological environment in vivo
earlier in the drug discovery process in order to improve the likelihood
of a drug succeeding at clinical trial." said
The Operetta system's new capabilities include brightfield imaging and environmental chamber options, and a new transmitted light digital phase-contrast mode that enables users to image and segment live cells without using fluorescent dyes. This feature reduces toxic effects of nuclear stains that may negatively impact the viability of cells, enabling longer and more predictive live cell studies. Furthermore, it can help to reduce assay costs.
In addition to the live cell imaging capabilities, the upgraded Operetta system is integrated with advanced informatics solutions, such as PerkinElmer's Columbus™ Image Data Storage and Analysis System for high content imaging data, and the TIBCO® Spotfire® software for data analysis and visualization which enables users to easily combine findings across experiments.
Visit www.perkinelmer.com/Operetta for more information
TIBCO and Spotfire are registered trademarks of TIBCO Software Inc.
Edelman (On behalf of
News Provided by Acquire Media